City

Bethesda (1)

Sioux Falls (1)

Sydney (1)

Overall Status

Completed (1)

Recruiting (1)

Withdrawn (1)

Phase

phase 1 (1)

phase 1/phase 2 (1)

Sponsor

National Cancer Institute (NCI) (1)

Sanford Health (1)

Vanderbilt-Ingram Cancer Center (1)

Intervention

capecitabine (1)

laboratory biomarker analysis (1)

pharmacological study (1)

temozolomide (1)

vandetanib (1)

veliparib (1)

Study Documents

Intervention Type

drug (2)

other (1)

Funder Type

Other (2)

NIH (1)

Study Type

Interventional (2)

Observational [Patient Registry] (1)

multiple endocrine neoplasia type 2b

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence Trial in Sioux Falls, Sydney

Recruiting

Rare Disorders
+309 more

Sioux Falls, South Dakota
+1 more

Jun 20, 2022

Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B Trial run by the NCI

Completed

Has Results

Medullary Thyroid Carcinoma
+2 more

Vandetanib

Bethesda, Maryland

National Institutes of Health Clinical Center, 9000 Rockville Pi

Dec 1, 2020

Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma, Merkel Cell Carcinoma Trial (Capecitabine, Temozolomide,

Withdrawn

Functional Pancreatic Neuroendocrine Tumor
+28 more

Capecitabine
+4 more

(no location specified)

Sep 26, 2017